GSK plc (GSK)
 NYSE: GSK · Real-Time Price · USD
 46.35
 -0.51 (-1.09%)
  At close: Nov 3, 2025, 4:00 PM EST
46.20
 -0.15 (-0.32%)
  Pre-market: Nov 4, 2025, 5:44 AM EST
GSK Revenue
GSK had revenue of 8.55B GBP in the quarter ending September 30, 2025, with 6.68% growth. This brings the company's revenue in the last twelve months to 32.17B, up 2.73% year-over-year. In the year 2024, GSK had annual revenue of 31.38B with 3.46% growth.
Revenue (ttm) 
 32.17B GBP
Revenue Growth 
 +2.73%
P/S Ratio 
 2.15
Revenue / Employee 
 468,694 GBP
Employees 
 68,629
Market Cap 
92.85B USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 31.38B | 1.05B | 3.46% | 
| Dec 31, 2023 | 30.33B | 1.00B | 3.42% | 
| Dec 31, 2022 | 29.32B | 4.63B | 18.74% | 
| Dec 31, 2021 | 24.70B | 342.00M | 1.40% | 
| Dec 31, 2020 | 24.35B | -9.40B | -27.85% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 64.24B | 
| AbbVie | 59.64B | 
| Eli Lilly and Company | 59.42B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Novo Nordisk | 49.11B | 
GSK News
- 5 days ago - GSK plc (GSK) Q3 2025 Earnings Call Transcript - Seeking Alpha
 - 5 days ago - GSK Upgrades 2025 Financial Outlook, CEO Says Positioned Well For 2026 - Benzinga
 - 6 days ago - GSK Raises Guidance After Sales, Earnings Growth - WSJ
 - 6 days ago - GSK raises 2025 sales forecast after strong growth in specialty medicines - Reuters
 - 10 days ago - GSK shares fall as narrow approval of blood cancer drug limits US relaunch - Reuters
 - 11 days ago - FTSE 100 Index shares to watch: HSBC, Standard Chartered, Haleon, GSK - Invezz
 - 11 days ago - Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma - Business Wire
 - 11 days ago - US FDA approve GSK's blood cancer treatment - Reuters